

Development and first results of the BEAT-PCD international Primary Ciliary Dyskinesia gene variant database: CiliaVar

R. Mani¹, M. Gomes², A. R. González³, C. Hogg⁴, D. Morris-Rosendahl⁵, B. Maitre⁶, M. R. Fassad³, M. Goutaki⁷, J. S. Lucas⁸, A. Shoemark⁹, H. M. Mitchison³, S. Crowley¹⁰, M. Legendre¹¹

¹Sorbonne Université, Inserm UMR_S933 Génétique des maladies pédiatriques, Hôpital Armand-Trousseau, Paris; Unité de recherche "Biologie moléculaire des leucémies et lymphomes", UR14ES19, Faculté de Médecine de Sousse, Université de Sousse, Sousse - Paris (France), ²Genetics and Genomic Medicine Department, University College London, UCL Great Ormond Street Institute of Child Health; University of Dundee - London (United Kingdom), ³Genetics and Genomic Medicine Department, University College London, UCL Great Ormond Street Institute of Child Health - London (United Kingdom), ⁴Royal Brompton Hospital and Imperial College - London (United Kingdom), ⁵Clinical Genetics and Genomics Laboratory, Royal Brompton Hospital and Imperial College - London (United Kingdom), ⁶Université Paris Est Créteil, Centre hospitalier intercommunal de Créteil - Paris (France), ⁷Institute of Social and Preventive Medicine, University of Bern, - Bern (Switzerland), ⁸University of Southampton Faculty of Medicine, School of Clinical and Experimental Sciences - Southampton (United Kingdom), ⁹University of Dundee; Royal Brompton Hospital - Dundee (United Kingdom), ¹⁰Paediatric Department of Allergy and Lung Diseases - Oslo (Norway), ¹¹Sorbonne Université, Inserm UMR_S933 Génétique des maladies pédiatriques, Hôpital Armand-Trousseau - Paris (France)



ERS Clinical Research Collaboration

Introduction

Primary Ciliary Dyskinesia (PCD) is a motile ciliopathy due to bi-allelic pathogenic mutations in one of more than **50 genes**.

Most of the mutations are **private** (identified in a single family).

New **variants of unknown significance (VUS)** are constantly being identified. As clinical genetic testing is increasingly used for PCD, there is a need to develop a **public access resource** to identify if variants have previously been associated with the disease.

Objectives and Methods

We are developing an **online open database** collecting **mutations** and **specific combinations of mutations** causing PCD.

A panel of clinicians and molecular geneticists with expertise in PCD identified relevant items to be linked to each variant, among **clinical, ciliary and genetic investigations** supporting pathogenicity. An extensive literature search was conducted to identify published mutations. Database curators checked mutation nomenclature and classification following the American College of Medical Genetics (ACMG) guidelines.

Data census and curation steps

	Literature search 651 papers
	Abstracts review 262 selected papers
	Patients 1551 from literature 201 from a diagnostic centre
	Mutations 1267
	Mutation nomenclature verification and classification following ACMG guidelines


CiliaVar

Mutation spectrum


Recurrent mutations 22% (n=279)
Private mutations 78% (n=988)

Results

Genetic spectrum in 1551 independent PCD patients



Classification of 1267 distinct mutations reported in the 1551 PCD patients



The most common recurrent mutations reported are *CCDC40* c.248del (n=41 patients) and *DNAH11* c.48+2dupT (n=49) (ancestral European alleles).

20% of the 1267 distinct mutations are classified as VUS and 93% of those VUS are missense mutations.

The online open database CiliaVar (beta-testing) will facilitate access to PCD variant information to improve the diagnosis of PCD.